The primary objective of this study was to evaluate the formulation, Pharmacological Evaluation, and Efficacy Studies of Occidiofungin, a Novel Antifungal. This report investigates different courses of organization and details of occidiofungin, as well as its toxicity in mice. Further, infections studies contemplates were acted in mice to survey the utilization of occidiofungin for treating systematic and intravaginal yeast diseases. Definitions for intravenous and intravaginal organization of occidiofungin were prepared. Toxicological and histopathological analyses of two repeat-dose studies using occidiofungin were performed. Pharmacokinetic analyses were performed in a murine model, and a liquid chromatography-mass spectrometry (LC-MS) method was developed and used to quantify occidiofungin in mouse plasma samples. As a result it was found that limitations in the use of occidiofungin that may be alleviated with the development of novel structural analogs or with further formulation studies. These results provide a clear indication for the use of occidiofungin for the treatment of recurrent vulvovaginal candidiasis (RVVC). This report indeed outlines all the optimal routes of administration of occidiofungin and demonstrates minimal toxicity following chronic exposure.
Reference link- https://aac.asm.org/content/64/12/e01737-20
